(Reuters) -Telehealth firm Hims & Hers Health said on Tuesday it plans to sell Eli Lilly's diabetes and weight-loss drugs on ...

Hims & Hers Health (NYSE:HIMS) stock gains as the company adds Eli Lilly's (LLY) weight loss therapy tirzepatide & generic ...

Mumbai: As the global demand for GLP-1 class drugs for diabetes and obesity management surged, Mumbai-based gut health start-up The Good Bug introduced a ‘GLP-1-based formulation’ designed to support ...

Eli Lilly (LLY) is taking legal action against makers of off-brand versions of its blockbuster diabetes and weight-loss drugs ...

The Good Bug’s formulation, priced at Rs 2,000 per month, is based on microbiome research. A randomised, double-blinded, ...

The Trump administration’s cuts to a global AIDS relief program threaten to upend rollout of a groundbreaking HIV prevention ...

Eli Lilly sues two compounders over tirzepatide after FDA lifts Zepbound, Mounjaro shortage status in key GLP-1 legal test.

Mounjaro, a GLP-1 receptor agonist, works by slowing digestion and suppressing appetite, leading to reduced caloric intake ...

Eli Lilly is suing Strive Pharmacy and Empower Pharmacy for compounding tirzepatide, the active ingredient in Zepbound and ...

Lately, however, Eli Lilly's stock has cooled. Shares have been essentially flat since July 2024. The market for GLP-1 ...

But while tariffs will affect US consumers and companies as well as those further afield, some businesses may be either ...